Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach

Cost Effectiveness of Angiotensin Receptor Blocker Monotherapy in Patients with Hypertension in the Netherlands

(2010) Cornelis Boersma et al.   American Journal of Cardiovascular Drugs

Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: Results of a longitudinal, population-based study

(2010) Michael R. Law et al.   CLINICAL THERAPEUTICS

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension

(2010) J. Signorovitch et al.   CURRENT MEDICAL RESEARCH AND OPINION

Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension

(2010) Lesley-Ann Miller et al.   CURRENT MEDICAL RESEARCH AND OPINION

Prior Authorization for Antidepressants in Medicaid

(2009) Alyce S. Adams et al.   ARCHIVES OF INTERNAL MEDICINE

Hypertension guidelines

(2009) Christopher E Clark et al.   BRITISH JOURNAL OF GENERAL PRACTICE

Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review

(2009) Peter Bramlage et al.   Cardiovascular Diabetology

Valsartan Improves Endothelial Dysfunction in Hypertension: A Randomized, Double-Blind Study

(2009) Nikolaos Tzemos et al.   Cardiovascular Therapeutics

Nebivolol: A third-generation β-blocker for hypertension

(2009) Judy W.M. Cheng   CLINICAL THERAPEUTICS

The value of irbesartan in the management of hypertension

(2009) Peter Bramlage et al.   EXPERT OPINION ON PHARMACOTHERAPY

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach

(2009) R. M. Nixon et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept

(2009) Massimo Volpe et al.   JOURNAL OF HYPERTENSION

Les recommandations et le guide « Affections de longue durée » dans l’hypertension artérielle sévère

(2009) Jean-Marc Boivin et al.   PRESSE MEDICALE

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

(2009) Eugen Florin Georgescu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Long-Term Effects of Angiotensin II Receptor Blockade with Valsartan on Carotid Arterial Stiffness and Hemodynamic Alterations in Patients with Essential Hypertension

(2008) Takafumi Okura et al.   CLINICAL AND EXPERIMENTAL HYPERTENSION

Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers)

(2008) Antonio Coca   CLINICAL DRUG INVESTIGATION

New guidelines of the European society of hypertension

(2008) Julian Segura et al.   CURRENT HYPERTENSION REPORTS

Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen

(2008) J. D. Belsey   CURRENT MEDICAL RESEARCH AND OPINION

Cost-Effectiveness Analysis: Controlled-Release Nifedipine and Valsartan Combination Therapy in Patients with Essential Hypertension: The Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) Study

(2008) Ikuo SAITO et al.   HYPERTENSION RESEARCH

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on

(2008) J. Usher-Smith et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden

(2008) M Ekman et al.   JOURNAL OF HUMAN HYPERTENSION

A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension

(2008) M. Kosch et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION